Sugimoto, Masahiko
Wakamatsu, Yasuko
Miyata, Ryohei
Nunome, Takayasu
Tenma, Yumiho
Matsubara, Hisashi
Kondo, Mineo
Wada, Hideo
Nakatani, Kaname
Funding for this research was provided by:
Novartis | Alcon | Alcon Research Institute
Article History
Received: 14 September 2018
Accepted: 31 July 2019
First Online: 26 August 2019
Competing Interests
: Masahiko Sugimoto have competing financial interests: COI [F] Alcon Pharma (class III), Bayer (class III) [I/E/C/P] None [R] Alcon pharma (class II), Kowa Pharma (class II), Senjyu Pharma (class II), Daiichi Yakuhin Sangyo (class II), Bayer (class II), Wakamoto Pharma (class II) Masahiko Sugimoto declare competing non-financial interests.